ERBB2 and cancer: This may be partially attributed to differences in the composition of immune cells within the infiltrate and it may indicate that, despite a favorable response to chemotherapy, other–possibly ER-related pathways–are contributing to the poor prognosis in this subgroup of luminal Her-2-negative cancers.